Strategies for the development of conotoxins as new therapeutic leads

Marine Drugs

Volumn 11, Issue 7, 2013, Pages 2293-2313

  Brady, Ryan M ^a   Baell, Jonathan B ^a   Norton, Raymond S ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Cone snail; Ion channel; Pain; Peptide toxin; Peptidomimetic

Indexed keywords

2 AMINOBENZAMIDE; ALPHA CONOTOXIN IMI; ALPHA CONOTOXIN PNIA; ALPHA CONOTOXIN VC1.1; ANALGESIC AGENT; ARGININE; BENZAMIDE; BENZOTHIAZOLE; CALCIUM CHANNEL BLOCKING AGENT; CAV2.1 CHANNEL; CAV2.2 CHANNEL; CONOTOXIN; DIKETOPIPERAZINE CARBOXAMIDE; DIPHENYLMETHYLPIPERAZINE; DISULFIDE; GABAPENTIN; HISTIDINE; LEUCINE; LYSINE; MU CONOTOXIN BUIIIC; MU CONOTOXIN KIIIA; NP 180809; OMEGA CONOTOXIN GVIA; OMEGA CONOTOXIN MVIIA; PEPTIDOMIMETIC AGENT; PIPERAZINE DERIVATIVE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

AMINO ACID SIDE CHAIN; CHRONIC PAIN; COMPUTER MODEL; CONUS GEOGRAPHUS; CONUS KINOSHITAI; CYCLIZATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; NEUROPATHIC PAIN; NONHUMAN; PHARMACOPHORE; PROTEIN CONFORMATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; SNAIL; STRUCTURE ACTIVITY RELATION;

GASTROPODA;

ANIMALS; AQUATIC ORGANISMS; CONOTOXINS; HUMANS; PEPTIDES;

EID: 84880898626     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md11072293     Document Type: Review

References (122)

1. Lewis, R.J.; Dutertre, S.; Vetter, I.; Christie, M.J. Conus venom peptide pharmacology. Pharm. Rev. 2012, 64, 259-298.
2. Olivera, B.M.; Hillyard, D.R.; Marsh, M.; Yoshikami, D. Combinatorial peptide libraries in drug design-Lessons from venomous cone snails. Trends Biotechnol. 1995, 13, 422-426.
3. Livett, B.G.; Gayler, K.R.; Khalil, Z. Drugs from the sea: Conopeptides as potential therapeutics. Curr. Med. Chem. 2004, 11, 1715-1723.
4. French, R.J.; Terlau, H. Sodium channel toxins-Receptor targeting and therapeutic potential. Curr. Med. Chem. 2004, 11, 3053-3064.
5. Norton, R.S.; Olivera, B.M. Conotoxins down under. Toxicon 2006, 48, 780-798.
6. Olivera, B.M.; Rivier, J.; Clark, C.; Ramilo, C.A.; Corpuz, G.P.; Abogadie, F.C.; Mena, E.E.; Woodward, S.R.; Hillyard, D.R.; Cruz, L.J. Diversity of Conus neuropeptides. Science 1990, 249, 257-263.
7. Terlau, H.; Olivera, B.M. Conus venoms: A rich source of novel ion channel-targeted peptides. Physiol. Rev. 2004, 84, 41-68.
8. Layer, R.T.; McIntosh, J.M. Conotoxins: Therapeutic potential and application. Mar. Drugs 2006, 4, 119-142.
9. Olivera, B.M.; Cruz, L.J. Conotoxins, in retrospect. Toxicon 2001, 39, 7-14.
10. Norton, R.S. μ-Conotoxins as leads in the development of new analgesics. Molecules 2010, 15, 2825-2844.
11. Alewood, P.; Hopping, G.; Armishaw, C. Marine toxins as sources of drug leads. Aust. J. Chem. 2003, 56, 769-774.
12. Kaas, Q.; Yu, R.L.; Jin, A.H.; Dutertre, S.; Craik, D.J. Conoserver: Updated content, knowledge, and discovery tools in the conopeptide database. Nucl. Acids. Res. 2012, 40, D325-D330.
13. Violette, A.; Biass, D.; Dutertre, S.; Koua, D.; Piquemal, D.; Pierrat, F.; Stocklin, R.; Favreau, P. Large-Scale discovery of conopeptides and conoproteins in the injectable venom of a fish-hunting cone snail using a combined proteomic and transcriptomic approach. J. Proteomics 2012, 75, 5215-5225.
14. Hu, H.; Bandyopadhyay, P.K.; Olivera, B.M.; Yandell, M. Elucidation of the molecular envenomation strategy of the cone snail Conus geographus through transcriptome sequencing of its venom duct. BMC Genomics 2012, 13, 284.
15. Brust, A.; Palant, E.; Croker, D.E.; Colless, B.; Drinkwater, R.; Patterson, B.; Schroeder, C.I.; Wilson, D.; Nielsen, C.K.; Smith, M.T.; et al. χ-Conopeptide pharmacophore development: Toward a novel class of norepinephrine transporter inhibitor (xen2174) for pain. J. Med. Chem. 2009, 52, 6991-7002.
16. Carstens, B.B.; Clark, R.J.; Daly, N.L.; Harvey, P.J.; Kaas, Q.; Craik, D.J. Engineering of Conotoxins for the treatment of pain. Curr. Pharm. Des. 2011, 17, 4242-4253.
17. Daly, N.L.; Craik, D.J. Conopeptides as novel options for pain management. Drugs Future 2011, 36, 25-32.
18. Bowersox, S.S.; Luther, R. Pharmacotherapeutic potential of ω-conotoxin MVIIA (snx-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 1998, 36, 1651-1658.
19. Miljanich, G.P. Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 2004, 11, 3029-3040.
20. Kumar, T.R.S.; Soppimath, K.; Nachaegari, S.K. Novel delivery technologies for protein and peptide therapeutics. Curr. Pharm. Biotechnol. 2006, 7, 261-276.
21. Hamman, J.H.; Enslin, G.M.; Kotze, A.F. Oral delivery of peptide drugs-Barriers and developments. Biodrugs 2005, 19, 165-177.
22. Adessi, C.; Soto, C. Converting a peptide into a drug: Strategies to improve stability and bioavailability. Curr. Med. Chem. 2002, 9, 963-978.
23. Ripka, A.S.; Rich, D.H. Peptidomimetic design. Curr. Opin. Chem. Biol. 1998, 2, 441-452.
24. Croft, N.P.; Purcell, A.W. Peptidomimetics: Modifying peptides in the pursuit of better vaccines. Expert Rev. Vaccines 2011, 10, 211-226.
25. Smith, A.B.; Charnley, A.K.; Hirschmann, R. Pyrrolinone-Based peptidomimetics. "Let the enzyme or receptor be the judge". Acc. Chem. Res. 2011, 44, 180-193.
26. Vagner, J.; Qu, H.C.; Hruby, V.J. Peptidomimetics, a synthetic tool of drug discovery. Curr. Opin. Chem. Biol. 2008, 12, 292-296.
27. Norton, R.S.; Pallaghy, P.K.; Baell, J.B.; Wright, C.E.; Lew, M.J.; Angus, J.A. Polypeptide ω-conotoxin GVIA as a basis for new analgesic and neuroprotective agents. Drug Dev. Res. 1999, 46, 206-218.
28. Norton, R.S.; McDonough, S.I. Peptides targeting voltage-gated calcium channels. Curr. Pharm. Des. 2008, 14, 2480-2491.
29. Menzler, S.; Bikker, J.A.; Suman-Chauhan, N.; Horwell, D.C. Design and biological evaluation of non-peptide analogues of ω-conotoxin MVIIA. Bioorg. Med. Chem. Lett. 2000, 10, 345-347.
30. Olivera, B.M.; Gray, W.R.; Zeikus, R.; McIntosh, J.M.; Varga, J.; Rivier, J.; Desantos, V.; Cruz, L.J. Peptide neurotoxins from fish-hunting cone snails. Science 1985, 230, 1338-1343.
31. Olivera, B.M.; Rivier, J.; Scott, J.K.; Hillyard, D.R.; Cruz, L.J. Conotoxins. J. Biol. Chem. 1991, 266, 22067-22070.
32. Guo, Z.X.; Cammidge, A.N.; Horwell, D.C. Dendroid peptide structural mimetics of ω-conotoxin MVIIA based on a 2(1H)-quinolinone core. Tetrahedron 2000, 56, 5169-5175.
33. Menzler, S.; Bikker, J.A.; Horwell, D.C. Synthesis of a non-peptide analogue of ω-conotoxin MVIIA. Tetrahedron Lett. 1998, 39, 7619-7622.
34. McCleskey, E.W.; Fox, A.P.; Feldman, D.H.; Cruz, L.J.; Olivera, B.M.; Tsien, R.W.; Yoshikami, D. ω-Conotoxin-Direct and persistent blockade of specific types of calcium channels in neurons but not muscle. Proc. Natl. Acad. Sci. USA 1987, 84, 4327-4331.
35. Olivera, B.M.; McIntosh, J.M.; Cruz, L.J.; Luque, F.A.; Gray, W.R. Purification and sequence of A presynaptic peptide toxin from Conus geographus venom. Biochemistry 1948, 23, 5087-5090.
36. Lew, M.J.; Flinn, J.P.; Pallaghy, P.K.; Murphy, R.; Whorlow, S.L.; Wright, C.E.; Norton, R.S.; Angus, J.A. Structure-function relationships of ω-conotoxin GVIA-Synthesis, structure, calcium channel binding, and functional assay of alanine-substituted analogues. J. Biol. Chem. 1997, 272, 12014-12023.
37. Flinn, J.P.; Pallaghy, P.K.; Lew, M.J.; Murphy, R.; Angus, J.A.; Norton, R.S. Roles of key functional groups in ω-conotoxin GVIA-Synthesis, structure and functional assay of selected peptide analogues. Eur. J. Biochem. 1999, 262, 447-455.
38. Baell, J.B.; Forsyth, S.A.; Gable, R.W.; Norton, R.S.; Mulder, R.J. Design and synthesis of type-III mimetics of omega-conotoxin GVIA. J. Comput. Aided Mol. Des. 2001, 15, 1119-1136.
39. Baell, J.B.; Duggan, P.J.; Forsyth, S.A.; Lewis, R.J.; Lok, Y.P.; Schroeder, C.I. Synthesis and biological evaluation of nonpeptide mimetics of ω-conotoxin GVIA. Bioorg. Med. Chem. 2004, 12, 4025-4037.
40. Duggan, P.J.; Lewis, R.J.; Lok, Y.P.; Lumsden, N.G.; Tuck, K.L.; Yang, A.J. Low molecular weight non-peptide mimics of ω-conotoxin GVIA. Bioorg. Med. Chem. Lett. 2009, 19, 2763-2765.
41. Baell, J.B.; Duggan, P.J.; Forsyth, S.A.; Lewis, R.J.; Lok, Y.P.; Schroeder, C.I.; Shepherd, N.E. Synthesis and biological evaluation of anthranilamide-based non-peptide mimetics of ω-conotoxin GVIA. Tetrahedron 2006, 62, 7284-7292.
42. Andersson, A.; Baell, J.B.; Duggan, P.J.; Graham, J.E.; Lewis, R.J.; Lumsden, N.G.; Tranberg, C.E.; Tuck, K.L.; Yang, A.J. ω-Conotoxin GVIA mimetics based on an anthranilamide core: Effect of variation in ammonium side chain lengths and incorporation of fluorine. Bioorg. Med. Chem. 2009, 17, 6659-6670.
43. Duggan, P.J.; Faber, J.M.; Graham, J.E.; Lewis, R.J.; Lumsden, N.G.; Tuck, K.L. Synthesis and Ca(v)2.2 binding data for non-peptide mimetics of ω-conotoxin GVIA based on a 5-Amino-Anthranilamide core. Aust. J. Chem. 2008, 61, 11-15.
44. Tranberg, C.E.; Yang, A.J.; Vetter, I.; McArthur, J.R.; Baell, J.B.; Lewis, R.J.; Tuck, K.L.; Duggan, P.J. ω-Conotoxin GVIA mimetics that bind and inhibit neuronal Ca(v)2.2 ion channels. Mar. Drugs 2012, 10, 2349-2368.
45. Zamponi, G.W.; Feng, Z.P.; Zhang, L.Y.; Pajouhesh, H.; Ding, Y.B.; Belardetti, F.; Dolphin, D.; Mitscher, L.A.; Snutch, T.P. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg. Med. Chem. Lett. 2009, 19, 6467-6472.
46. Pajouhesh, H.; Feng, Z.P.; Ding, Y.B.; Zhang, L.Y.; Morrison, J.L.; Belardetti, F.; Tringham, E.; Simonson, E.; Vanderah, T.W.; Porreca, F.; et al. Structure-Activity relationships of diphenylpiperazine N-type calcium channel inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 1378-1383.
47. Scott, V.E.; Vortherms, T.A.; Niforatos, W.; Swensen, A.M.; Neelands, T.; Milicic, I.; Banfor, P.N.; King, A.; Zhong, C.M.; Simler, G.; et al. A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats. Biochem. Pharmacol. 2012, 83, 406-418.
48. Doherty, G.A.; Bhatia, P.; Vortherms, T.A.; Marsh, K.C.; Wetter, J.M.; Mack, H.; Scott, V.E.; Jarvis, M.F.; Stewart, A.O. Discovery of diphenyl lactam derivatives as N-type calcium channel blockers. Bioorg. Med. Chem. Lett. 2012, 22, 1716-1718.
49. Bulaj, G.; West, P.J.; Garrett, J.E.; Marsh, M.; Zhang, M.M.; Norton, R.S.; Smith, B.J.; Yoshikami, D.; Olivera, B.M. Novel conotoxins from Conus striatus and Conus kinoshitai selectively block TTX-resistant sodium channels. Biochemistry 2005, 44, 7259-7265.
50. Knapp, O.; McArthur, J.R.; Adams, D.J. Conotoxins targeting neuronal voltage-gated sodium channel subtypes: Potential analgesics? Toxins (Basel) 2012, 4, 1236-1260.
51. Zhang, M.-M.; Green, B.R.; Catlin, P.; Fiedler, B.; Azam, L.; Chadwick, A.; Terlau, H.; McArthur, J.R.; French, R.J.; Gulyas, J.; et al. Structure/function characterization of μ-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J. Biol. Chem. 2007, 282, 30699-30706.
52. McArthur, J.R.; Singh, G.; McMaster, D.; Winkfein, R.; Tieleman, D.P.; French, R.J. Interactions of key charged residues contributing to selective block of neuronal sodium channels by μ-conotoxin KIIIA. Mol. Pharmacol. 2011, 80, 573-584.
53. Khoo, K.K.; Feng, Z.-P.; Smith, B.J.; Zhang, M.-M.; Yoshikami, D.; Olivera, B.M.; Bulaj, G.; Norton, R.S. Structure of the analgesic μ-conotoxin KIIIA and effects on the structure and function of disulfide deletion. Biochemistry 2009, 48, 1210-1219.
54. Khoo, K.K.; Gupta, K.; Green, B.R.; Zhang, M.M.; Watkins, M.; Olivera, B.M.; Balaram, P.; Yoshikami, D.; Bulaj, G.; Norton, R.S. Distinct disulfide isomers of μ-conotoxins KIIIA and KIIIB block voltage-gated sodium channels. Biochemistry 2012, 51, 9826-9835.
55. Brady, R.M.; Zhang, M.M.; Gable, R.B.; Norton, R.S.; Baell, J.B. De novo design and synthesis of a μ-KIIIA peptidomimetic. Bioorg. Med. Chem. Lett. 2013, in press.
56. Lessene, G.; Smith, B.J.; Gable, R.W.; Baell, J.B. Characterization of the two fundamental conformations of benzoylureas and elucidation of the factors that facilitate their conformational interchange. J. Org. Chem. 2009, 74, 6511-6525.
57. Herbert, R.H.; Kelleher, F. The solution conformation of 1-(3, 5-dimethylphenyl)methyl-3 (S)-(1H-indol-3-yl)methyl-6(S)-phenylmethyl-2, 5-piperazinedione(1)-An NMR and molecular modeling study. Tetrahedron Lett. 1994, 35, 5497-5500.
58. Kopple, K.D.; Marr, D.H. Conformations of cyclic peptides. Folding of cyclic dipeptides containing an aromatic side chain. J. Am. Chem. Soc. 1967, 89, 6193-6200.
59. Babine, R.E.; Bender, S.L. Molecular recognition of protein-ligand complexes: Applications to drug design. Chem. Rev. 1997, 97, 1359-1472.
60. Brady, R.M.; Tae, H.; Adams, D.J.; Zhang, M.M.; Norton, R.S.; Baell, J.B. Monash Institute of Pharmaceutical Science, Monash University, Parkville 3052, Australia. Unpublished work, 2013.
61. Jin, A.H.; Daly, N.L.; Nevin, S.T.; Wang, C.I.A.; Dutertre, S.; Lewis, R.J.; Adams, D.J.; Craik, D.J.; Alewood, P.F. Molecular engineering of conotoxins: The importance of loop size to α-conotoxin structure and function. J. Med. Chem. 2008, 51, 5575-5584.
62. Sine, S.M.; Kreienkamp, H.J.; Bren, N.; Maeda, R.; Taylor, P. Molecular dissection of subunit interfaces in the acetylcholine-receptor-Identification of determinants of α-conotoxin M1 selectivity. Neuron 1995, 15, 205-211.
63. Hu, S.H.; Gehrmann, J.; Guddat, L.W.; Alewood, P.F.; Craik, D.J.; Martin, J.L. The 1.1 angstrom crystal structure of the neuronal acetylcholine receptor antagonist, α-conotoxin PnIA from Conus pennaceus. Structure 1996, 4, 417-423.
64. Kirby, D.A.; Britton, K.T.; Aubert, M.L.; Rivier, J.E. Identification of high-potency neuropeptide Y analogues through systematic lactamization. J. Med. Chem. 1997, 40, 210-215.
65. Yao, S.G.; Smith-White, M.A.; Potter, E.K.; Norton, R.S. Stabilization of the helical structure of Y2-selective analogues of neuropeptide Y by lactam bridges. J. Med. Chem. 2002, 45, 2310-2318.
66. Yang, B.; Liu, D.X.; Huang, Z.W. Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-Apoptotic Bcl-2 family proteins. Bioorg. Med. Chem. Lett. 2004, 14, 1403-1406.
67. Shepherd, N.E.; Abbenante, G.; Fairlie, D.P. Consecutive cyclic pentapeptide modules form short α-helices that are very stable to water and denaturants. Angew. Chem. Int. Ed. 2004, 43, 2687-2690.
68. Shepherd, N.E.; Hoang, H.N.; Abbenante, G.; Fairlie, D.P. Left- And right-handed α-helical turns in homo- And hetero-chiral helical scaffolds. J. Am. Chem. Soc. 2009, 131, 15877-15886.
69. Lanigan, M.D.; Pennington, M.W.; Lefievere, Y.; Rauer, H.; Norton, R.S. Designed peptide analogues of the potassium channel blocker ShK toxin. Biochemistry 2001, 40, 15528-15537.
70. Khoo, K.K.; Wilson, M.J.; Smith, B.J.; Zhang, M.M.; Gulyas, J.; Yoshikami, D.; Rivier, J.E.; Bulaj, G.; Norton, R.S. Lactam-stabilized helical analogues of the analgesic μ-conotoxin KIIIA. J. Med. Chem. 2011, 54, 7558-7566.
71. Zhang, M.M.; Han, T.S.; Olivera, B.M.; Bulaj, G.; Yoshikami, D. μ-Conotoxin KIIIA derivatives with divergent affinities versus efficacies in blocking voltage-gated sodium channels. Biochemistry 2010, 49, 4804-4812.
72. Holford, M.; Zhang, M.M.; Gowd, K.H.; Azam, L.; Green, B.R.; Watkins, M.; Ownby, J.P.; Yoshikami, D.; Bulaj, G.; Olivera, B.M. Pruning nature: Biodiversity-derived discovery of novel sodium channel blocking conotoxins from Conus bullatus. Toxicon 2009, 53, 90-98.
73. Stevens, M.; Peigneur, S.; Dyubankova, N.; Lescrinier, E.; Herdewijn, P.; Tytgat, J. Design of bioactive peptides from naturally occurring μ-conotoxin structures. J. Biol. Chem. 2012, 287, 31382-31392.
74. Khoo, K.K.; Norton, R.S. Role of Disulfide Bonds in Peptide and Protein Conformation. In Amino Acids, Peptides and Proteins in Organic Chemistry; Wiley-VCH Verlag: Weinheim, Germany; Volume 5, pp. 395-417.
75. Muttenthaler, M.; Andersson, A.; de Araujo, A.D.; Dekan, Z.; Lewis, R.J.; Alewood, P.F. Modulating oxytocin activity and plasma stability by disulfide bond engineering. J. Med. Chem. 2010, 53, 8585-8596.
76. Armishaw, C.J.; Daly, N.L.; Nevin, S.T.; Adams, D.J.; Craik, D.J.; Alewood, P.F. α-Selenoconotoxins, a new class of potent α7 neuronal nicotinic receptor antagonists. J. Biol. Chem. 2006, 281, 14136-14143.
77. Stymiest, J.L.; Mitchell, B.F.; Wong, S.; Vederas, J.C. Synthesis of biologically active dicarba analogues of the peptide hormone oxytocin using ring-closing metathesis. Org. Lett. 2003, 5, 47-49.
78. Bondebjerg, J.; Grunnet, M.; Jespersen, T.; Meldal, M. Solid-Phase synthesis and biological activity of a thioether analogue of conotoxin G1. ChemBioChem 2003, 4, 186-194.
79. Galande, A.K.; Bramlett, K.S.; Burris, T.P.; Wittliff, J.L.; Spatola, A.F. Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions. J. Peptide Res. 2004, 63, 297-302.
80. Rew, Y.; Malkmus, S.; Svensson, C.; Yaksh, T.L.; Chung, N.N.; Schiller, P.W.; Cassel, J.A.; DeHaven, R.N.; Goodman, M. Synthesis and biological activities of cyclic lanthionine enkephalin analogues: δ-Opioid receptor selective ligands. J. Med. Chem. 2002, 45, 3746-3754.
81. Blackwell, H.E.; Sadowsky, J.D.; Howard, R.J.; Sampson, J.N.; Chao, J.A.; Steinmetz, W.E.; O'Leary, D.J.; Grubbs, R.H. Ring-closing metathesis of olefinic peptides: Design, synthesis, and structural characterization of macrocyclic helical peptides. J. Org. Chem. 2001, 66, 5291-5302.
82. Khan, S.N.; Kim, A.; Grubbs, R.H.; Kwon, Y.U. Ring-Closing metathesis approaches for the solid-phase synthesis of cyclic peptoids. Org. Lett. 2011, 13, 1582-1585.
83. Miller, S.J.; Blackwell, H.E.; Grubbs, R.H. Application of ring-closing metathesis to the synthesis of rigidified amino acids and peptides. J. Am. Chem. Soc. 1996, 118, 9606-9614.
84. Miller, S.J.; Grubbs, R.H. Synthesis of conformationally restricted amino-Acids and peptides employing olefin metathesis. J. Am. Chem. Soc. 1995, 117, 5855-5856.
85. Robinson, A.J.; Elaridi, J.; van Lierop, B.J.; Mujcinovic, S.; Jackson, W.R. Microwave-Assisted RCM for the synthesis of carbocyclic peptides. J. Peptide Sci. 2007, 13, 280-285.
86. Robinson, A.J.; van Lierop, B.J.; Garland, R.D.; Teoh, E.; Elaridi, J.; Illesinghe, J.P.; Jackson, W.R. Regioselective formation of interlocked dicarba bridges in naturally occurring cyclic peptide toxins using olefin metathesis. Chem. Commun. 2009, 28, 4293-4295.
87. Van Lierop, B.J.; Bornschein, C.; Jackson, W.R.; Robinson, A.J. Ring-closing metathesis in peptides-The sting is in the tail! Aust. J. Chem. 2011, 64, 806-811.
88. Richardson, J.S. The anatomy and taxonomy of protein structure. Adv. Protein Chem. 1981, 34, 167-339.
89. Hase, S.; Morikawa, T.; Sakakiba, S. Synthesis of A biologically active analog of deamino-8-Arginine-vasopressin which does not contain a disulfide bond. Experientia 1969, 25, 1239-1240.
90. Kambayashi, Y.; Nakajima, S.; Ueda, M.; Inouye, K. A dicarba analog of β-Atrial natriuretic peptide (β-Anp) inhibits guanosine 3′, 5′-cyclic-monophosphate production induced by α-Anp in cultured rat vascular smooth-muscle cells. FEBS Lett. 1989, 248, 28-34.
91. Oka, T.; Nakanishi, A.; Okada, T. Studies on pharmacological and biochemical properties of deamino-dicarba-[Gly7]-oxytocin (Y-5350). Jpn. J. Pharmacol. 1975, 25, 15-24.
92. Stymiest, J.L.; Mitchell, B.F.; Wong, S.; Vederas, J.C. Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability. J. Org. Chem. 2005, 70, 7799-7809.
93. Knerr, P.J.; Tzekou, A.; Ricklin, D.; Qu, H.C.; Chen, H.; van der Donk, W.A.; Lambris, J.D. Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin. ACS Chem. Biol. 2011, 6, 753-760.
94. McIntosh, J.M.; Yoshikami, D.; Mahe, E.; Nielsen, D.B.; Rivier, J.E.; Gray, W.R.; Olivera, B.M. A nicotinic acetylcholine-receptor ligand of unique specificity, α-conotoxin ImI. J. Biol. Chem. 1994, 269, 16733-16739.
95. MacRaild, C.A.; Illesinghe, J.; van Lierop, B.J.; Townsend, A.L.; Chebib, M.; Livett, B.G.; Robinson, A.J.; Norton, R.S. Structure and activity of (2, 8)-dicarba-(3, 12)-cystino α-ImI, an α-conotoxin containing a nonreducible cystine analogue. J. Med. Chem. 2009, 52, 755-762.
96. Robinson, A.J. Monash University, Clayton 3800, Australia. Personal communication, 2013.
97. Van Lierop, B.J.; Robinson, S.D.; Kompella, S.N.; McArthur, J.R.; Hung, A.; MacRaild, C.A.; Adams, D.J.; Norton, R.S.; Robinson, A.J. Dicarba α-conotoxin Vc1.1 analogues with differential selectivity for nicotinic acetylcholine and GABAB receptors. ACS Chem. Biol. 2013, in press.
98. Dekan, Z.; Vetter, I.; Daly, N.L.; Craik, D.J.; Lewis, R.J.; Alewood, P.F. α-Conotoxin ImI incorporating stable cystathionine bridges maintains full potency and identical three-dimensional structure. J. Am. Chem. Soc. 2011, 133, 15866-15869.
99. Bock, J.E.; Gavenonis, J.; Kritzer, J.A. Getting in shape: Controlling peptide bioactivity and bioavailability using conformational constraints. ACS Chem. Biol. 2013, 8, 488-499.
100. Adessi, C.; Soto, C. Strategies to improve stability and bioavailability of peptide drugs. Front. Med. Chem.Online 2004, 1, 513-528.
101. Craik, D.J.; Adams, D.J. Chemical modification of conotoxins to improve stability and activity. ACS Chem. Biol. 2007, 2, 457-468.
102. Boger, D.L. Vancomycin, teicoplanin, and ramoplanin: Synthetic and mechanistic studies. Med. Res. Rev. 2001, 21, 356-381.
103. Boger, D.L.; Kim, S.H.; Mori, Y.; Weng, J.H.; Rogel, O.; Castle, S.L.; McAtee, J.J. First and second generation total synthesis of the teicoplanin aglycon. J. Am. Chem. Soc. 2001, 123, 1862-1871.
104. Borel, J.F. Mechanism of action of cyclosporine-A and rationale for use in nephrotic syndrome. Clin. Nephrol. 1991, 35, S23-S30.
105. Allison, S.J. Basic research: An oral cyclic peptide drug to reverse kidney fibrosis? Nat. Rev. Nephrol. 2012, 8, 193-193.
106. Clark, R.J.; Akcan, M.; Kaas, Q.; Daly, N.L.; Craik, D.J. Cyclization of conotoxins to improve their biopharmaceutical properties. Toxicon 2012, 59, 446-455.
107. Clark, R.J.; Jensen, J.; Nevin, S.T.; Callaghan, B.P.; Adams, D.J.; Craik, D.J. The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew. Chem. Int. Ed. 2010, 49, 6545-6548.
108. Clark, R.J.; Fischer, H.; Nevin, S.T.; Adams, D.J.; Craik, D.J. The synthesis, structural characterization, and receptor specificity of the α-conotoxin Vc1.1. J. Biol. Chem. 2006, 281, 23254-23263.
109. Satkunanathan, N.; Livett, B.; Gayler, K.; Sandall, D.; Down, J.; Khalil, Z. α-Conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res. 2005, 1059, 149-158.
110. Vincler, M.; Wittenauer, S.; Parker, R.; Ellison, M.; Olivera, B.M.; McIntosh, J.M. Molecular mechanism for analgesia involving specific antagonism of α9, α10 nicotinic acetylcholine receptors. Proc. Natl. Acad. Sci. USA 2006, 103, 17880-17884.
111. Vincler, M.; McIntosh, J.M. Targeting the α9, α10 nicotinic acetylcholine receptor to treat severe pain. Expert Opin. Ther. 2007, 11, 891-897.
112. Callaghan, B.; Haythornthwaite, A.; Berecki, G.; Clark, R.J.; Craik, D.J.; Adams, D.J. Analgesic α-conotoxins Vc1.1 and RgIA inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation. J. Neurosci. 2008, 28, 10943-10951.
113. Callaghan, B.; Adams, D.J. Analgesic α-conotoxins Vc1.1 and RgIA inhibit N-type calcium channels in sensory neurons of α9 nicotinic receptor knockout mice. Channels (Austin) 2010, 4, 51-54.
114. Cuny, H.; de Faoite, A.; Huynh, T.G.; Yasuda, T.; Berecki, G.; Adams, D.J. γ-Aminobutyric acid type B (GABAB) receptor expression is needed for inhibition of N-type (Cav2.2) calcium channels by analgesic α-conotoxins. J. Biol. Chem. 2012, 287, 23948-23957.
115. Green, B.R.; Catlin, P.; Zhang, M.M.; Fiedler, B.; Bayudan, W.; Morrison, A.; Norton, R.S.; Smith, B.J.; Yoshikami, D.; Olivera, B.M.; et al. Conotoxins containing nonnatural backbone spacers: Cladistic-based design, chemical synthesis, and improved analgesic activity. Chem. Biol. 2007, 14, 399-407.
116. Veronese, F.M.; Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005, 10, 1451-1458.
117. Doyle, M.E.; Greig, N.H.; Holloway, H.W.; Betkey, J.A.; Bernier, M.; Egan, J.M. Insertion of an N-terminal 6-Aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-Acting hypoglycemic agent. Endocrinology 2001, 142, 4462-4468.
118. Langer, M.; la Bella, R.; Garcia-Garayoa, E.; Beck-Sickinger, A.G. Tc-99m-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconjugate Chem. 2001, 12, 1028-1034.
119. Rist, B.; Wieland, H.A.; Willim, K.D.; Beck-Sickinger, A.G. A rational approach for the development of reduced-size analogues of neuropeptide Y with high affinity to the Y-1 receptor. J. Peptide Sci. 1995, 1, 341-348.
120. Wang, C.Z.; Zhang, H.; Jiang, H.; Lu, W.Y.; Zhao, Z.Q.; Chi, C.W. A novel conotoxin from Conus striatus, μ-SIIIA, selectively blocking rat tetrodotoxin-resistant sodium channels. Toxicon 2006, 47, 122-132.
121. Hunskaar, S.; Hole, K. The formalin test in mice-Dissociation between inflammatory and noninflammatory pain. Pain 1987, 30, 103-114.
122. Han, T.S.; Zhang, M.M.; Walewska, A.; Gruszczynski, P.; Robertson, C.R.; Cheatham, T.E.; Yoshikami, D.; Olivera, B.M.; Bulaj, G. Structurally minimized μ-conotoxin analogues as sodium channel blockers: Implications for designing conopeptide-based therapeutics. ChemMedChem 2009, 4, 406-414.